Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M

SOLENO THERAPEUTICS INC

2025-Q2 EPS reported -$1.00 revenue$32,657,000

Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.
Cash, equivalents & marketable securities at June 30, 2025: ~$293.8 million.
Received 646 patient start forms from ~295 unique prescribers since March 26, 2025 approval.
Debt outstanding under Oxford Financing LLC loan: ~$50.0 million, unchanged.
First revenue quarter for VYKAT XR; financial close and review ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.